Previous 10 | Next 10 |
home / stock / zldpf / zldpf news
Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review designation to dasiglucagon for the prevention and treatment of hypoglycemia in pedia...
2023-08-17 12:42:18 ET Zealand Pharma press release ( OTCPK:ZLDPF ): 1H revenue of Kr.24M (-33.9% Y/Y). Net operating result Kr. -364.0 million vs Kr. -434.1 million. For further details see: Zealand Pharma reports 1H results
Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance sheet Boehringer Ingelheim to move into Phase 3 trials with GCGR/GLP-1R dual agonis...
Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the...
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6...
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discove...
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean of 4.2% from baseline (4.8% placebo-corrected) within one week following a single dose of ZP...
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906) 1 Up to 40% of people who reached the highest two do...
2023-05-11 14:06:10 ET Zealand Pharma A/S. (ZEAL) Q1 2023 Earnings Conference Call May 11, 2023, 08:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO Henriette Wennicke - CFO David Kendall - CMO Conference Call Part...
Company announcement - No. 20 / 2023 Zealand Pharma Announces Financial Results for the First Quarter of 2023 Positive topline data from obesity portfolio On track for two regulatory submissions targeting rare diseases Strengthened balance sheet with DKK 1.5 billio...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...